NOV
14

VOLUNTARY ANNOUNCEMENT VESTING OF AWARD SHARES

NOV
14

THE GROUP'S PRODUCT CEFUROXIME SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

NOV
07

VOLUNTARY ANNOUNCEMENT ACQUISITION OF AWARD SHARES

OCT
25

THE GROUP'S PRODUCT CEFTAZIDIME FOR INJECTION PASSED THE CONSISTENCY EVALUATION

OCT
16

THE GROUP'S PRODUCT AMOXICILLIN GRANULES PASSED THE CONSISTENCY EVALUATION

OCT
14

UPDATED INFORMATION ON THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION

OCT
14

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT TUL12101 EYE DROPS

SEP
25

SUPPLEMENTAL ANNOUNCEMENT THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

SEP
25

Interim dividend for the six months ended 30 June 2024

SEP
25

PAYMENT OF 2024 INTERIM DIVIDEND

AUG
30

Interim dividend for the six months ended 30 June 2024

AUG
29

Interim Results Announcement for the six months ended 30 June 2024

AUG
15

POSITIVE PROFIT ALERT

AUG
15

DATE OF BOARD MEETING

AUG
12

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION

JUL
01

Special dividend for the year ended 31 December 2023

JUL
01

Final dividend for the year ended 31 December 2023

JUN
28

PAYMENT OF 2023 FINAL DIVIDEND AND SPECIAL DIVIDEND

JUN
20

POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING

JUN
11

List of Directors and Their Role and Function

JUN
03

CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE MASTER SALES AGREEMENT

MAY
07

Special dividend for the year ended 31 December 2023

MAY
07

Final dividend for the year ended 31 December 2023

MAY
07

CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE FOR FINAL DIVIDEND AND SPECIAL DIVIDEND

APR
29

NOTICE OF ANNUAL GENERAL MEETING

APR
24

UPDATED INFORMATION ON THE GROUP'S PRODUCT AMOXICILLIN CLAVULANATE POTASSIUM TABLETS

APR
23

VOLUNTARY ANNOUNCEMENT PROPOSED BID-WINNING RESULTS OF NATIONAL CENTRALISED PROCUREMENT OF PHARMACEUTICALS (SPECIALISING RENEWAL IN INSULIN)

APR
02

Special dividend for the year ended 31 December 2023

APR
02

Final dividend for the year ended 31 December 2023

MAR
27

2023 ANNUAL RESULTS ANNOUNCEMENT

MAR
14

POSITIVE PROFIT ALERT

MAR
11

DATE OF BOARD MEETING

JAN
17

UPDATED INFORMATION ON THE GROUP'S PRODUCT - IMIPENEM AND CILASTATIN SODIUM FOR INJECTION